Psychiatry and human rights: Putting the good of patient first;Psiquiatría y derechos humanos: La prioridad es el bien del paciente: Discurso de aceptación del premio juan josé lópez ibor

Actas Espanolas de Psiquiatria

Volumn 37, Issue 1, 2009, Pages 1-8

  Eisenberg, Leon ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHICS; HUMAN RIGHTS; PATIENT RIGHT; PSYCHIATRY; REVIEW;

HUMAN RIGHTS; PATIENT RIGHTS; PSYCHIATRY;

EID: 62749175745     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Parks, J, Svendsend D, Singer P, Foti ME. Morbidity and Mortality in People with Serious Mental Illness. Morbidity and Mortality Weekly Report (October, 2006). www.NASMHPD.org.
2. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007; 64(10):1123-1131.
3. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psycholog Med 1999; 29:697-701.
4. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177:212-217.
5. Osborn DPJ, Levy G, Nazareth l, Petersen l, lslam A, King H. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Arch Gen Psychiatry 2007; 64:242-249.
6. Lewis A. Letter from Britain. Am J Psychiatry 1953; 110:404-405.
7. Craddock N, Antebi D, Attenburrow M J, Bailey A, Carson A, Co-wen P, et al. Wake-up call for British psychiatry. Br J Psychiatry 2008; 193:6-9.
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Diseases, First edition. Washington, DC: American Psychiatric Association; 1952.
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Diseases, Second edition. Washington, DC: American Psychiatric Association; 1968.
10. Mojtabai R, Olfson M. National trends in psychotherapy by office-based psychiatrists. Arch Gen Psychiatry 2008;65:962-970.
11. Eisenberg L. The right to health care: for patients or for profits? Am J Psychiatry 1986a;143:1015-1019.
12. Brecht B. Life of Galileo. En J Willet, R Manheim (Eds.). New York: Arcade Publishing;1940,1994.
13. Medical Research Council. Streptomycin treatment of tuberculous meningitis. Lancet 1948;1:582-596.
14. Medical Research Council. Streptomycin treatment for pulmonary tuberculosis. Br Med J 1948;11:769-782.
15. Beeson PB. Changes in medical therapy during the past half-century. Medicine 1980;59:79-99.
16. Frank JD. Persuasion and Healing. Baltimore: The Johns Hopkins Press; 1961.
17. Rogow A. The Psychiatrists. New York: Putnam; 1970.
18. Barton W, Malamud W. Training the psychiatrist to meet changing needs. Washington, DC: American Psychiatric Association;1963. p. 8.
19. Eisenberg L. Discussion. En: PH Hoch, J Zubin (Eds). The Future of Psychiatry. New York: Grune and Stratton; 1962a. p. 251-255.
20. Rosenfield AH. Psychiatric Education: Prologue to the 1980s. Washington, DC: American Psychiatric Association; 1976.
21. Eisenberg L. If not now, when? Am J Orthopsychiatr 1962b; 32:781-93.
22. Conners CK. Clinical Use of Stimulant Drugs in Children: Proceedings of a Symposium held at Key Biscayne, Florida, 5-8 March, 1972. New York: American Elsevier Publishing Co., Inc; 1974.
23. Cytryn L, Gilbert A, Eisenberg L The effectiveness of tranquilizing drugs plus supportive psychotherapy in treating behavior disorders of children. Am J Orthopsychiatry 1960; 30:113-129.
24. Eisenberg L, Lachman R, Moiling P, Lockner A, Mizelle J, Conners K. A psychopharmacologic study in a training school for delinquent boys. Am J Orthopsychiatry 1963; 33:431-447.
25. Eisenberg L. The role of drugs in treating psychiatric disorders in children. Children 1964;11:167-173.
26. Eisenberg L. When «ADHD» was «the Brain-Damaged Child». J Child Adolesc Psychopharmacol 2007;17(3):279-283.
27. Eisenberg L. The need for evaluation. Am J Psychiatry 1968; 124:1700-1701.
28. Eisenberg L Psychiatric intervention. Scientific American 1973; 229:116-127.
29. Jones M. The Therapeutic Community. New York: Basic Books; 1952.
30. Shepherd M, Goodman N, Watt DC. The application of hospital statistics in the evaluation of pharmacotherapy in a psychiatric population. Comprehens Psychiatry 1961; 2:11-19.
31. Odegaard 0. Patterns of discharge from Norwegian psychiatric hospitals before and after the introduction of psychotropic drugs. Am J Psychiatry 1964;120:772-8.
32. Grob GN. The Mad Among Us. Cambridge, MA: Harvard University Press; 1994.
33. Catlin A, Cowan C, Hartman M, Hartman M, Heffer S, et al. National health spending in 2006: a year of change for prescription drugs. Health Affairs 2008;27(1):14-29.
34. Relman A. The new medical-industrial complex. New Eng J Med 1980; 303(17):963-970.
35. Mundy A. Drug industry boosts lobbying. The Wall Street Journal, 25 June 2008.
36. Klerman, GL. The Contemporary American Scene: Diagnosis and Classification of Mental Disorders, Alcoholism, and Drug Abuse. En: N Sartorius, A Jablensky, DA Regier, JD Burke, et al. (Eds). Sources and Traditions of Classification in Psychiatry. Bern: Huber; 1990. pp. 93-157.
37. Kramer M. Cross-national study of diagnosis of the mental disorders. Am J Psychiatry 1969;125(Suppl.l-ll).
38. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Diseases. Third edition. Washington: American Psychiatric Association; 1980.
39. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth edition. Washington, DC: American Psychiatric Association; 1994.
40. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Revised. Washington, DC: American Psychiatric Association; 2000.
41. Pursell B. APA staff (personal communication); 2008.
42. Cosgrove L, Krimsky S, Vijayaraghavan M, Schneider L. Financial Ties between DSM-IV Panel Members and the Pharmaceutical Industry. Psychother Psychosom 2006;75:154-160.
43. Meyer A. Conditions for a home of psychology in the medical curriculum. J Abnorm Psychol 1912;7:313-325.
44. E isenberg L. Psychiatry and society: a sociobiological synthesis. New Eng J Med 1977; 296:903-910.
45. Coronary Drug Research Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. New Eng J Med 1980; 303:1038-1041.
46. Jameson KR. An Unquiet Mind: A Memoir of Moods and Madness. New York: Alfred A. Knopf; 1995.
47. Ginzburg E. The monetarization of medical care. New Eng J Med 1984;310:1162-1165.
48. Eisenberg L. Mindlessness and brainlessness in psychiatry. Br J Psychiatry 1986b;148:497 508.
49. McKinlay JB, Arches J. Towards the proletarianization of physicians. Internat J Health Serv 1985;15:161-195.
50. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. New Eng J Med 2008; 358(3): 252-280.
51. Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment. J Am Med Association 2008;299(15):1813-1817.
52. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib. J Am Med Assoc 2008;299(15): 1800-1812.
53. Harris G. Pfizer to pay $430 million over promoting drug to doctors. New York Times, 14 May, 2004.
54. Melvin CL, Carey TS, Oldham JM. Introduction: Antiepileptic medications for bipolar disorder. J Psychiatric Practice 2008; 14(Suppl.1):7-8.
55. Dreifus C. Using imaging to look at changes in the brain: A conversation with Nancy C. Andreasen. New York Times (September 16, 2008).
56. Montoya ID, Lee-Dukes G, Shah D. Direct-to-consumer advertising: its effects on stakeholders. J Allied Health Health 2008; 37(2),116-120.
57. Kafka F. A country doctor. The Basic Franz Kafka. New York: Pocket Books; 1979.
58. Kowatch RA, Fristad M, Birmaher B, Wagner KD, Findling RL, Mellander M, et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005;44:213-235.
59. Healy D, LeNoury J. Pediatric bipolar disorder: An object of study in the creation of an illness. Internat J Risk Safety Med 2007;19(4):209-221.
60. Scully JH. Quoted in Headlines (a daily news briefing on psychiatry and mental health). 2008. p. 5.
61. Steinbrook R. Disclosure of industry payments to physicians. New Eng J Med 2008;359:557-559.
62. Campbell EG, Gruen RL, Mountford J, Miller LG, Cleary PH, Blumenthal D. A national survey of physician-industry relationships. New Eng J Med 2007;356:1742-1750.
63. Campbell EG, Weissman JS, Ehringhaus S, et al. Institutional academic-industry relationships. J Am Med Assoc 2007; 298:1779-1786.
64. Harris G, Carey B, Roberts J. Psychiatric children and drug industry's role. New York Times, 10 May, 2007.
65. Ross JS, Lacker JE, Lurie P, Gross CP, Wolfe S, Krumholz HM. Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota. J Am Med Assoc 2007; 297(13):1218-1223.
66. Goff SL, Mazor KM, Meterko BS, Dodd K, Sabin J. Patients' beliefs and preferences regarding doctors' medication recommendations. J Gen Intern Med 2008; 23(3):236-241.
67. Angell M. Industry-sponsored clinical research: a broken system. J Am Med Assoc 2008; 300(9): 1069-1071.
68. Fletcher SW. Continuing medical education. Br Med J 2008; 337:a1023.
69. Khan MM. Murky waters: the pharmaceutical industry and psychiatrists in developing countries. Psychiatric Bull 2006; 30:85-88.
70. Pisacane A. Rethinking continuing medical education. Br Med J 2008; 337:a973.
71. Relman A. Industry support of medical education. J Am Med Assoc 2008; 300:107-113.
72. Editorial. Credibility crisis in pediatric psychiatry. Nature Neuroscience 2008;11:983.
73. Association of American Medical Colleges 2008 Industry funding of medical education: report of an AAMC task force. https://services.aamc.org/ Publications/index.cfm ?fuseaction=Product.display-Form&prd-id=232&cfid= &tcftoken=AB8BBD70-8212-4F9F-8A9A3EB31698232E. Accessibility verified September 13, 2008.
74. American Medical Association Council on Ethical and Judicial Affairs. Industry support of professional education in medicine. http://www.AMA-Assn.org/ ama1/pub/upload/mm/471/ceja1-2.doc. Accessibility verified September 13, 2008.
75. Friedman M. Capitalism and Freedom. Chicago: University of Chicago Press; 1982.